Russia hopes to achieve pharmaceutical 'sovereignty' by 2030

Amid the ongoing military conflict between Ukraine and Russia and the ever-tightening sanctions pressure on Russia, the Kremlin is considering investing about 200 billion roubles ($12.1 billion) in the achievement of so-called medicine and pharmaceutical “sovereignty”.

The concept of the strategy, which aims to increase Russia's share of domestic drugs by up to 85% of the market as well as seeing it export at least 50 original domestic drugs, has already been prepared by the Russian Ministry of Education and Science and will be sent soon for consideration of the federal government, reports The Pharma Letter’s local correspondent.

In accordance with the concept, the current share of foreign drug manufacturers in the Russian market is estimated at 55% in value terms with a total market value of 2.3 trillion roubles, while in volume terms it is 33%, equivalent to 6.5 billion packages.